Search | Clinical Trials Finder

Conditions: Hyperacusis
Interventions: Sound therapy using low-level background sound, Remote counseling using HAT-Online, Sound therapy using successive approximations; Device · Behavioral · Other
Lead sponsor: Augustana College; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rock Island, Illinois

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,041 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 75
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more

Conditions: Congestive Heart Failure
Interventions: Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anxiety
Interventions: healing attempt; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cardiovascular Diseases
Interventions: Active choice, Passive choice; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 23,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Pracinostat, Placebos, Azacitidine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Antibody-mediated Rejection
Interventions: Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Aurora, Colorado • Clearwater, Florida • DeBary, Florida + 8 more

Conditions: Schizophrenia
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Diabetes Type 2
Interventions: BMS-770767, Placebo, Metformin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Lomita, California • Las Vegas, Nevada

Conditions: Systemic Lupus Erythematosus
Interventions: Group B SLE one blood donation, Blood drawing only Group C, Group A SLE prospective study; Other · Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 14 Years to 70 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Collegeville, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 50
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 40 more

Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions: FT819, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 16
States / cities: Beverly Hills, California • Fullerton, California • Irvine, California + 13 more

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions: ALXN2050, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin Benzoate, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 34
States / cities: Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin immediate release; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 45
States / cities: Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 52
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more

Search by objective public record fields.

A Feasibility Study of a Novel, Fully Remote Counseling and Sound Therapy Program for Hyperacusis

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Music-based Mindfulness Intervention for Elevated Race-based Anxiety in the Black Community

Active Choice in the EHR to Promote Statin Therapy

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Phase 3 Alogliptin Pediatric Study

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)